Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PULSE BIOSCIENCES, INC. (PLSE)

Pulse Biosciences Q3 revenue rises to $0.4 million; net loss widens to $23.1 million

Mixed Impact 3 of 5 earnings Written later

Pulse Biosciences reported third quarter 2026 revenue of $0.4 million, up from $0.1 million a year earlier, while its GAAP net loss widened to $23.1 million from $19.4 million. The company also said it completed enrollment in its U.S. pivotal NANOPULSE-AF study and ended the quarter with $189.2 million in cash, cash equivalents, and marketable securities, after raising $95.8 million through its ATM programs.

Key points

  • GAAP net loss was $23.1 million, or $0.32 per share, versus $19.4 million, or $0.29 per share, a year earlier.
  • Cash, cash equivalents, and marketable securities totaled $189.2 million as of September 30, 2026, compared with $101.6 million on June 30, 2026.
  • NANOPULSE-AF pivotal study completed enrollment with 169 evaluable patients, three months ahead of the original plan.

The filing

CompanyPULSE BIOSCIENCES, INC. (PLSE)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:07 PM ET
Accession number0001437749-26-035265

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.